Clinical results from a Phase IIb study conducted on 254 patients with primary insomnia showed positive effects for Merck’s MK-4305.

MK-4305 is Merck’s investigational dual-orexin receptor antagonist, which inhibits the actions of orexin A and orexin B – the chemical messengers important in the sleep-wake system.

The primary endpoint is improvement in sleep efficiency and the secondary endpoints are improvement in wake after sleep onset and latency to persistent sleep.

The Phase III trials showed that MK-4305 was more effective than a placebo at helping patients sleep longer on night one and at the end of four weeks of treatment.

The randomised, double-blind, placebo-controlled crossover study had been designed to evaluate the safety and efficacy of four doses of MK-4305 in patients with primary insomnia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.